Access cutting-edge non-small cell lung cancer treatment through this clinical trial at a research site in Anchorage. Study-provided care at no cost to qualified participants.
Access non-small cell lung cancer specialists in Anchorage at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-small cell lung cancer treatment provided free
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this non-small cell lung cancer clinical trial in Anchorage, AK
If you're searching for non-small cell lung cancer treatment options in Anchorage, AK, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Anchorage research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.